Urinary system neoplasm

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This study explores whether adding high-intensity interval training (HIIT) to standard immunotherapy (nivolumab plus ipilimumab) helps patients with advanced kidney cancer. Thirty participants are randomly assigned to either a supervised exercise program or usual care. Researcher…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This phase 2 trial tests whether giving focused radiation (SBRT) along with immunotherapy drugs (cemiplimab, with or without fianlimab) before bladder removal can safely shrink muscle-invasive bladder tumors. The study enrolls 44 patients who cannot or choose not to take standard…

This early-phase trial tests a combination of three drugs—enfortumab vedotin, pembrolizumab, and quemliclustat—in people with advanced bladder or urinary tract cancer that has spread or cannot be removed by surgery. The goal is to see if the combination is safe and effective. The…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This phase II trial compares a new targeted drug, sacituzumab tirumotecan (Sac-TMT), to other antibody-drug conjugates (ADCs) in people with advanced urothelial carcinoma (bladder cancer) that has worsened after prior treatment. The main goal is to see if Sac-TMT causes less seve…

This study tests whether giving focused radiation or surgery to all visible tumors (both the original kidney tumor and its metastases) can allow people with advanced kidney cancer to stop all cancer treatments for at least a year. Participants must have stable or partially improv…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This phase 2 trial tests whether a combination of two drugs—enfortumab vedotin (Padcev) and pembrolizumab (Keytruda)—can help people with muscle-invasive bladder cancer avoid bladder removal. About 56 participants will receive the drugs first, and those who respond well may get r…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This study looks at whether using ureteral stents (small tubes) after bladder cancer surgery leads to more or fewer problems than not using them. About 190 adults having their bladder removed will be randomly assigned to get stents or not. The main goal is to see who ends up back…

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-phase trial tests whether adding radiation therapy or bladder removal surgery can safely eliminate remaining cancer in patients with advanced bladder cancer who have already responded to a drug combination. The study enrolls 12 adults with muscle-invasive bladder cance…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This study tests whether combining two drugs (trastuzumab rezetecan and camrelizumab) before surgery can improve outcomes for people with a certain type of muscle-invasive bladder cancer (HER2-positive). About 44 adults will receive the treatment to see if it helps eliminate canc…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This phase 2 trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery to people with muscle-invasive bladder cancer or upper tract urothelial carcinoma. The goal is to see if the drugs can shrink or eliminate the cancer enough that some b…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This phase 2 trial tests whether adding a gene therapy called nadofaragene firadenovec to standard chemotherapy and immunotherapy can improve outcomes for people with muscle invasive bladder cancer before they have their bladder removed. The gene therapy is placed directly into t…

This study tests a new drug called AK146D1, given alone or with another drug (AK112), in people with advanced urothelial carcinoma (a type of bladder cancer). The goal is to see if the treatment is safe and can shrink tumors. About 132 adults aged 18-75 with measurable tumors and…

This early-stage trial tests a new drug called ATO-101 for a type of bladder cancer that hasn't responded to standard treatments. The drug delivers a short-range radioactive particle directly into the bladder to kill cancer cells while sparing healthy tissue. About 24 patients wi…

This early-phase trial is testing whether adding sitagliptin, a diabetes drug, to the immunotherapy pembrolizumab is safe and can help people with advanced kidney cancer or melanoma whose cancer has stopped responding to standard treatment. The study will first find the safest do…

This early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This Phase 2 trial tests whether giving two drugs (anlotinib and benmelstobart) before surgery can improve outcomes for people with localized kidney cancer. About 144 participants will either receive the drug combo followed by partial nephrectomy, or surgery alone. The main goal …

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…

This study looks at people with a very high-risk type of bladder cancer that cannot be fully removed with standard surgery. After initial treatment with immunotherapy and surgery, some patients become tumor-free. The trial then randomly assigns them to either continue immunothera…

This study tests whether adding the cholesterol drug atorvastatin to standard targeted therapy (axitinib) and immunotherapy (toripalimab) can help people with advanced kidney cancer who are not responding well to treatment. The drug combination is guided by lab tests on patient-d…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This Phase 3 trial is testing whether a combination of an experimental drug (SHR-1501) plus the standard immunotherapy BCG works better than chemotherapy for people with a type of bladder cancer (papillary-only NMIBC) that no longer responds to BCG alone. The study plans to enrol…

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This study tests whether giving two drugs (trastuzumab rezetecan and adebrelimab) before surgery can eliminate or shrink tumors in people with a specific type of muscle-invasive bladder cancer (HER2-positive). About 58 adults will receive the combination, then have their bladder …

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This study tests whether altering gut bacteria can restore the effectiveness of immunotherapy in people with advanced kidney cancer. About 33 adults will receive a bowel cleanse, a live bacterial supplement, and then a combination of immunotherapy drugs. The goal is to see if thi…

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…

This study tests whether a combination of disitamab vedotin (a targeted drug) and toripalimab (an immunotherapy) works better than standard chemotherapy plus immunotherapy for people with HER2-positive muscle-invasive bladder cancer. About 240 participants will receive treatment …

This study tests whether giving a combination of two drugs (a PD-L1 inhibitor called TQB2450 and anlotinib) before surgery can shrink complex kidney tumors enough to allow surgeons to remove only the tumor and save the rest of the kidney. About 33 adults with advanced clear cell …

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This study tests whether giving a combination of three drugs (pembrolizumab, belzutifan, and lenvatinib) before surgery can shrink kidney tumors in people with localized clear cell renal cell carcinoma. About 150 participants will receive the drugs for 12 weeks before surgery, th…

This study tests an experimental daily pill called zanzalintinib in 44 adults with advanced bladder cancer that has continued to grow after previous treatments. The goal is to see if the drug can shrink tumors or slow the cancer's progression. Participants will take the pill once…

This early-stage trial tests a new drug, REGN15505, alone or with other drugs, in adults with advanced prostate or kidney cancer that has spread. The goal is to help the immune system attack cancer cells. About 265 participants will be enrolled to check safety, side effects, and …

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This study tests a two-drug treatment (disitamab vedotin plus tislelizumab) for people with a rare, aggressive cancer of the upper urinary tract that has a specific marker (HER2-positive). The goal is to shrink the tumor so that the kidney can be saved, avoiding complete removal.…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This pilot phase II trial tests whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery is safe and feasible for patients with high-risk clear cell kidney cancer that hasn't spread. Sixteen participants will receive the drugs and then undergo surgery …

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This phase 2 trial tests whether adding a probiotic capsule (MO-03) to the drug zanzalintinib can help treat metastatic kidney cancer that has worsened after immunotherapy. About 34 adults with advanced clear cell renal cell carcinoma will receive both treatments. The goal is to …

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

This early-phase trial is testing a new treatment called LNK001 for people with advanced or metastatic clear cell renal cell carcinoma (a type of kidney cancer) that has not responded to standard treatments. LNK001 is a type of immunotherapy where a patient's own immune cells are…

This study tests a treatment called HIVEC, which delivers heated chemotherapy directly into the bladder. It is for people with a type of bladder cancer that has not responded to standard therapy and who cannot have their bladder removed. The goal is to see if this approach is saf…

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This early-phase study tests a new drug combination (L19IL2 plus ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 partici…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This phase 2 trial tests a new drug called zanzalintinib, taken as a pill, combined with a bone-strengthening agent for people with advanced kidney cancer that has spread to the bones. The study enrolls 20 participants whose cancer has worsened after 1–3 prior treatments, includi…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This early-stage trial tests a procedure called calcium electroporation for bladder tumors. Doctors inject calcium into the tumor and then apply short electric pulses to destroy cancer cells. The study will include 20 patients who cannot have standard surgery or other treatments.…

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This study tests a kidney-sparing approach for people with high-risk upper tract urothelial carcinoma, a cancer in the kidney or ureter. Instead of removing the whole kidney, participants get endoscopic surgery, targeted radiotherapy, and two drugs (disitamab vedotin and toripali…

This Phase 1 trial tests a new drug called HLX05-N, which is a biosimilar (a copy) of the cancer drug Erbitux, in 387 people with metastatic colorectal cancer. Participants will receive either HLX05-N or Erbitux (from the US or EU) along with standard chemotherapy. The study aims…

This early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a pro…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This Phase 1 trial tests whether HLX18, a biosimilar of the cancer drug OPDIVO, works similarly in people with esophageal, melanoma, or bladder cancer after their tumors have been surgically removed. About 174 participants will receive either HLX18 or OPDIVO to compare how the dr…

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This phase 3 study tests a new drug called SYS6002 against standard chemotherapy in 406 people with advanced bladder cancer (urothelial carcinoma) that has worsened after platinum chemo and immunotherapy. The main goal is to see if SYS6002 helps people live longer. The study is n…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This study tests whether adding a 5-day fasting-mimicking diet (low-calorie, low-protein) to the usual combination of toripalimab (an immunotherapy) and axitinib (a targeted drug) can help people with advanced kidney cancer. The trial will enroll 43 adults who have not had prior …

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This early study tests a new cell therapy called UCL70805F in 21 people with advanced clear cell kidney cancer that has not responded to standard treatments. The therapy uses immune cells designed to target a protein called CD70 on cancer cells. The main goals are to check safety…

This phase 2 study tests whether adding an immunotherapy drug (iparomlimab and tuvonralimab) and targeted radiation to a standard targeted therapy (fruquintinib) can help people with metastatic colorectal cancer that has spread to a few spots. The trial will enroll 60 adults who …

This study tests a new drug called WGI-0301 combined with the immunotherapy nivolumab in people with advanced liver or kidney cancer. The goal is to see if the combination is safe and can shrink tumors. About 230 adults aged 18 to 75 will take part, and the study does not use a p…

This study tests a new treatment for people with a rare cancer of the upper urinary tract (UTUC) that has spread beyond the kidney. Participants must have had surgery and cannot take standard chemo due to health reasons. They will receive either a targeted drug (disitamab vedotin…

This study tests if temporarily restricting blood flow to an arm (called ischemic preconditioning) before kidney cancer surgery can reduce kidney damage. About 174 adults having partial nephrectomy will be randomly assigned to receive this technique or standard care. The goal is …

This study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…

This phase 2 trial will test a combination of precise radiation (SBRT) and two drugs—anlotinib (which cuts off tumor blood supply) and bemarituzumab (which boosts the immune system)—in 27 people with advanced kidney cancer that cannot be surgically removed. The main goal is to se…

This study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This study tests whether adding a probiotic (Clostridium butyricum) to a combination of targeted therapy (Disitamab Vedotin) and immunotherapy (Toripalimab) can help preserve the bladder in people with muscle-invasive bladder cancer who cannot take the chemotherapy drug cisplatin…

This early-stage trial tests a new drug called JL19001, given alone or with standard BCG therapy, in 18 people with high-risk non-muscle invasive bladder cancer. The main goals are to check safety, find the right dose, and see how the body handles the drug. It's a first step to s…

This study watches 226 adults with small kidney tumors (stage T1a) who get radiofrequency ablation, a treatment that uses heat to destroy cancer cells. Researchers will track how well the procedure works and any side effects. No extra treatments or tests are given—just normal car…

This Phase 3 trial tests NDV-01, a sustained-release combination of two chemotherapy drugs (gemcitabine and docetaxel), given directly into the bladder. It aims to prevent cancer from coming back in people with non-muscle invasive bladder cancer, including those who have not resp…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This study tests a new treatment called HS-10566, a gel that delivers the chemotherapy drug gemcitabine directly into the bladder. It is for people with high-risk non-muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. The trial will check if th…

This study tests whether combining two drugs, pembrolizumab and lenvatinib, can help people with advanced kidney cancer (clear cell type) whose cancer returned after prior immunotherapy. About 108 adults will receive the combination to see if it shrinks tumors or delays cancer gr…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This study tests whether the drug avelumab can help keep metastatic urothelial carcinoma (a type of bladder cancer) from growing after patients have already received two lines of chemotherapy. About 144 adults whose cancer has not worsened after second-line chemo will receive ave…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…

This study tests a drug called sacituzumab tirumotecan in 20 people with a rare and aggressive kidney cancer (SMARCB1-deficient renal medullary carcinoma) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink or control the cancer. Resear…

This early-phase trial tests a new biologic drug called SPGL008, given alone or with the standard therapy BCG, in 120 people with high-risk non-muscle-invasive bladder cancer who are not candidates for bladder removal. The main goals are to find a safe dose and see if the drug ca…

This phase 3 trial tests a radioactive drug called Lu-177 PSMA in 20 people with metastatic clear cell kidney cancer that has worsened after at least two prior treatments. The drug is designed to seek out and destroy cancer cells while limiting damage to healthy tissue. Researche…

This study tests whether adding immunotherapy (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with muscle-invasive bladder cancer. About 30 participants will receive the combination therapy, and researchers will monitor how the tumor and immu…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This study tests whether giving two drugs (toripalimab and 9MW2821) before surgery can improve outcomes for people with localized upper tract urothelial carcinoma, a type of cancer in the kidney or ureter. About 40 adults will be randomly assigned to either the drug combo followe…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This study looks at whether veterans with early-stage high-grade bladder cancer can have fewer follow-up exams (cystoscopies) without harming their health. About 2,500 participants will be randomly assigned to either a low-intensity or high-intensity surveillance schedule. The go…

This study compares two treatments for muscle-invasive bladder cancer: radiation combined with chemotherapy versus surgery to remove the bladder. About 336 adults with this cancer will be randomly assigned to one of the two groups. The goal is to see if the non-surgical approach …

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This Phase 2 trial compares a new drug called SYS6002 to the current standard treatment PADCEV in 100 people with advanced bladder cancer that has worsened after chemotherapy and immunotherapy. The study is not yet recruiting and will check for side effects and how well the drugs…

This early-phase trial tests a new drug called TPD3310 in 112 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive weekly injections over 28-day cycl…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This phase 2 trial tests a virus-based drug given directly into the bladder for people with high-risk non-muscle invasive bladder cancer. The virus is designed to attack cancer cells and trigger the immune system. About 18 participants will receive increasing doses to find the sa…

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests a new drug combination (SHR-1811 plus bevacizumab) as a second-line treatment for people with metastatic colorectal cancer that has worsened after initial therapy. About 80 adults aged 18-75 will participate. The goal is to see if the combo shrinks tumors and del…

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This study looks at whether getting standard immunotherapy drugs (nivolumab and ipilimumab) in the morning or afternoon makes a difference for people with advanced kidney cancer. About 142 adults will be randomly assigned to morning or afternoon infusions. Researchers will track …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This study follows 159 Chinese patients with triple-class exposed relapsed/refractory multiple myeloma who are taking elranatamab in routine care. Researchers will track how well the drug controls the cancer, including response rates and survival. The goal is to see if elranatama…

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This phase 2 trial tests a combination of two drugs (toripalimab and RC48-ADC) plus radiation in 45 people with HER2-positive muscle-invasive bladder cancer. The goal is to see if this approach can eliminate the cancer and allow patients to keep their bladder after initial chemot…

This study tests a highly precise type of radiation called SBRT for people with kidney cancer who cannot undergo surgery. The treatment uses a robotic system (CyberKnife) to deliver high-dose radiation directly to the tumor while sparing healthy tissue. Researchers will track 60 …

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This early study tests a new treatment called Plasma-Activated Saline Solution (PASS) for bladder cancer. Five patients will receive a one-week course of PASS infused directly into the bladder before their scheduled surgery. Researchers will check if the treatment shrinks tumors …

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib or axitinib) in 36 adults with advanced clear cell kidney cancer that has worsened after initial treatment. The main goal is to see if the combination can …

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…

This phase 3 trial compares radiotherapy with a radiosensitiser to the standard BCG immunotherapy for high-risk non-muscle invasive bladder cancer. About 328 patients will be randomly assigned to one of the two treatments after tumor removal. The goal is to see which approach bet…

This clinical trial is for adults with metastatic clear cell kidney cancer. It compares having surgery to remove the kidney tumor either before or after starting immunotherapy drugs (ipilimumab and nivolumab). The goal is to see which timing helps people live longer without the c…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This study tests a new combination of the drug entinostat plus standard chemotherapy for people with advanced bladder cancer that has spread or cannot be removed by surgery and has not responded to first-line treatment. About 29 participants will receive the combination to see if…

This phase 2 trial tests a combination of two drugs, envafolimab and lenvatinib, as a first treatment for people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 participants and measure how well the drugs shrink liver tumors. It is not yet rec…

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This phase 2 trial tests a combination of RP2 (a modified herpes simplex virus that targets and destroys tumor cells) and tivozanib (a drug that blocks tumor blood vessel growth) in 35 patients with metastatic kidney cancer that worsened after immunotherapy. The goal is to see if…

This phase 2 trial tests whether a drug called N-803, combined with either BCG or gemcitabine, can treat intermediate-risk bladder cancer without needing surgery. About 20 adults with low-grade papillary tumors will receive the drugs directly into the bladder. The main goal is to…

This study tests whether adding the drug disitamab vedotin to standard BCG therapy can help keep high-risk, early-stage bladder cancer from returning. It includes 182 adults whose cancer has been surgically removed but is at high risk of coming back. Participants will receive eit…

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This early study will test a new type of immune cell therapy in 20 people with advanced bladder cancer that hasn't responded to standard treatments. The therapy uses the patient's own γδ-T cells, which are grown in a lab and then infused back to attack the cancer. The main goal i…

This study tests whether injecting the chemotherapy drug gemcitabine directly into the bladder wall can prevent cancer from coming back in people with intermediate- or high-risk non-muscle-invasive bladder cancer. About 320 participants will receive either the new injection or th…

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This study tests whether two drugs, Vedisertib and Toripalimab, can shrink muscle-invasive bladder cancer so patients can keep their bladder. About 59 adults with early-stage cancer will receive the drugs in cycles, with regular checks to see if the cancer disappears. If it does,…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …

This phase 2 trial tests a new drug called JS004, a BTLA antibody, combined with toripalimab (an immunotherapy) in 31 people with advanced kidney cancer that has worsened after prior immunotherapy. The goal is to see if the combination can shrink tumors or slow disease progressio…

This study tests whether adding chemotherapy drugs (gemcitabine and mitomycin C) directly into the bladder alongside an immune-boosting drug (toripalimab) works better than toripalimab alone for people with a high-risk bladder cancer that did not respond to standard BCG therapy. …

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…

This study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…

This phase 2 trial tests a dose-dense (faster) schedule of two chemotherapy drugs, gemcitabine and cisplatin, given before surgery for muscle-invasive bladder cancer. The goal is to see if this approach can completely eliminate the tumor in the bladder and lymph nodes. Thirty eli…

This phase 3 trial tests whether a combination of two drugs, vorolanib and everolimus, can help people with advanced kidney cancer whose disease has worsened after immunotherapy. About 116 participants will be randomly assigned to receive either the combo or the standard drug sun…

This early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…

This study tests a combination of two drugs—envafolimab (an immunotherapy injection) and axitinib (a targeted therapy pill)—as a first treatment for people with advanced kidney cancer that has spread or cannot be removed. About 30 participants will receive the treatment for up to…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…

This phase 2 trial tests two drugs—disitamab vedotin and toripalimab—as a way to treat HER2-positive muscle-invasive bladder cancer without removing the bladder. About 60 adults with locally advanced cancer will receive different cycles of the combination. The main goal is to see…

This study looks at whether giving radiation therapy after surgery can help prevent high-risk adrenocortical carcinoma from coming back. Fifty-eight patients who had their tumor completely removed will be randomly assigned to either receive radiation or just be monitored. The mai…

This early-phase study tests a new imaging agent called RYZ512 in 10 people with advanced clear cell kidney cancer that has spread. The agent is designed to attach to a protein (CAIX) found on these cancer cells, making them show up on scans. The goal is to see if it is safe and …

This early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study will test an artificial intelligence system that screens for breast, liver, kidney, and bladder cancers using standard CT scans taken for other reasons. Researchers plan to enroll 100,000 participants to see if the AI can catch tumors earlier and help doctors reduce mi…

This study tests if a very thin, single-use camera can be used in a doctor's office to look for cancer in the upper urinary tract, instead of doing it in an operating room under general anesthesia. Ten adults with known or suspected upper tract urothelial carcinoma will undergo t…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study explores whether analyzing tumor DNA in urine can be a simple, non-invasive way to monitor prostate and bladder cancer. Researchers will collect urine samples from 25 patients at different treatment stages to see if the test can detect cancer mutations and track change…

This study tests whether a special PET scan using a drug called 89Zr-girentuximab can detect kidney cancer that remains or comes back after initial treatment. Ten adults with clear cell renal cell carcinoma will receive the drug and then have a PET scan. Some will also have a sec…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This study looks for protein markers in urine and blood that could help identify different types of kidney cancer without needing a biopsy. Researchers will analyze stored urine samples from 300 people and collect blood before and after kidney removal surgery. The goal is to deve…

This study tests whether a special PET scan using 82-Rb can tell how aggressive a kidney tumor is. Doctors will compare the scan results to the actual tumor grade after surgery. If it works, patients might avoid unnecessary biopsies or surgeries. The study involves 50 adults with…

This study tests a urine test (Xpert Bladder Cancer Detect) to see if it can accurately identify people with hidden blood in their urine who are at higher risk for bladder cancer. About 1,475 adults over 40 will provide a urine sample and answer symptom questionnaires, then under…

This observational study will test an artificial intelligence model that can automatically detect and diagnose kidney tumors and cysts using non-contrast CT scans. Researchers aim to enroll 10,000 patients to build a system that distinguishes between cysts, benign growths, and ma…

This study tests whether a special PET scan (FAPI PET) and simple urine tests can better determine the stage of bladder cancer compared to standard methods. About 262 adults with bladder cancer will receive the scan and provide urine samples before treatment. The goal is to see i…

This study aims to see if a special MRI scan can accurately diagnose invasive upper urinary tract tumors. About 178 adults with suspicious findings on a CT scan will receive an MRI, and the results will be compared to standard biopsy or follow-up CT. If successful, MRI could offe…

This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…

This study tests whether a single dose of the drug disitamab vedotin, given directly into the bladder right after kidney removal surgery, can prevent bladder cancer from coming back. It involves 49 adults with HER2-positive upper tract cancer who are at risk for recurrence. The m…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) can prevent postoperative delirium in elderly patients undergoing urological surgery. Researchers will apply TMS to the left frontal lobe during anesthesia and monit…

This study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study looks at whether a prehabilitation program—including physical therapy, dietary advice, and emotional support—given before major cancer surgery can reduce deaths and serious complications within 30 days after the operation. About 180 adults with cancers of the pancreas,…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study looks at whether a supportive product called Neuridase can help reduce nerve damage (peripheral neuropathy) caused by a combination of two cancer drugs (enfortumab vedotin and pembrolizumab) in people with advanced bladder cancer. About 40 participants will receive sta…

This early-stage study will give 20 bladder cancer patients cannabigerol (CBG) gummies before and after surgery to see if they are safe and tolerable. The goal is to improve quality of life and reduce symptoms during recovery. Researchers will monitor side effects and how well pa…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This study tests whether adding acupuncture to virtual exercise can help manage nerve pain caused by a specific bladder cancer treatment (EV-Pembro). About 50 adults with advanced bladder cancer will be split into two groups: one gets acupuncture plus virtual exercise, the other …

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This study looks at whether giving standard bladder cancer drugs in the morning or afternoon changes how well they work and how many side effects they cause. About 224 adults with advanced bladder cancer will be randomly assigned to receive their treatment either before 11:30 a.m…

This study tests a newer, more precise radiation method (adaptive radiotherapy) for people with muscle-invasive bladder cancer who cannot have surgery or choose not to. The goal is to see if this technique reduces bowel side effects like diarrhea compared to standard radiation. A…

This study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…

This study tests a behavioral program to help women who have had pelvic radiation use vaginal dilators more regularly. Dilators can prevent or treat vaginal narrowing that makes exams or sex painful. 88 women will be randomly assigned to either the program (with coping strategies…

This study tests a new robotic system called LARC that helps surgeons precisely guide a needle into the kidney during surgery for large kidney stones. The goal is to make the procedure safer and faster by reducing the need for a separate pre-surgery step. Up to 45 adults will be …

This study tests whether small changes—like playing calming music, showing a relaxing video, or giving numbing gel at the right time—can reduce pain and anxiety during a bladder cancer exam or treatment. About 378 adults with bladder cancer will be randomly assigned to receive on…

This study tests whether a video call with a family member while waiting in the operating room can lower stress, anxiety, and fear in patients having bladder tumor surgery. About 124 adults will be randomly assigned to either have a video call or receive standard care. Researcher…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study planned to test whether kidneys with small, low-risk tumors could be removed from donors, have the tumor taken out, and then be transplanted into patients with kidney failure. The goal was to increase the number of available donor kidneys. However, the study was withdr…

This study will enroll 200 adults aged 60 or older who are scheduled for major surgery for urologic cancer. Researchers want to see if an artificial intelligence analysis of a standard heart test (ECG) taken before surgery can predict whether a patient will suffer heart injury or…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study looks at how a special program, called the Geriatric Surgery Verification Program, works at the James Cancer Hospital. The program helps doctors and nurses better care for patients aged 65 and older who need cancer surgery. It includes checking for age-related issues l…

This study will compare two types of robot-assisted surgery for prostate or kidney cancer: single-port (one small incision) and multi-port (several incisions). Researchers will track 376 adults to see which approach leads to a shorter hospital stay and better recovery. The study …

This study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This pilot study will test whether a flexible scope inserted into the urinary tract (ureterorenoscopy) under local anesthesia is safe and feasible for monitoring upper tract urothelial cancer in 10 people who have had kidney-sparing surgery. The main goal is to see if the procedu…

This study will include 2,600 adults scheduled for bladder tumor surgery. Half will get a standard urine culture before surgery; the other half will not. The goal is to see if skipping the test leads to more fevers or infections in the month after surgery. If it's safe, it could …

This study will test a special AI program called UroMed AI Doctor, designed to help with urology care. Researchers will compare AI-assisted care to traditional care from a specialist for patients with kidney stones, enlarged prostate, or bladder cancer. The goal is to see if the …

This study will test whether immunotherapy drugs (immune checkpoint inhibitors) change how the liver processes other medications. About 80 adults with various cancers who are starting immunotherapy will take a low-dose cocktail of 7 common drugs. Researchers will measure drug lev…

This study examines two microscopic details in bladder cancer tumors—how deep early cancer cells have invaded and whether small clusters of cells are present at the tumor's edge. Researchers will look at tissue samples from 100 patients to see if these features can predict if the…

This study examines stored tumor samples from 100 bladder cancer patients who had their bladder removed. Researchers will measure the amount of supportive tissue, immune cells, and immune clusters near the tumor. The goal is to see if these features are linked to how long patient…

This study will follow 300 people with non-spreading bladder cancer who receive high-dose radiation therapy (with or without a chemotherapy booster). Researchers want to see how long patients live, how often the cancer returns in the bladder or elsewhere, and what side effects oc…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy before surgery. Researchers will collect blood and tumor samples at several time points to see how the immune system responds. …

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study looks back at how well a combination of two drugs—enfortumab vedotin and pembrolizumab—works as the first treatment for people with advanced bladder cancer that has spread. Researchers will collect data from 361 patients around the world to see how long they live and h…

This study will test a new classification system (BICEP) to grade bladder injuries that happen during a common surgery for bladder cancer called TURBT. Researchers will observe 1,000 patients to see how often injuries occur, how severe they are, and how doctors manage them. The g…

This study looks at how age and sex influence pain before and after a first-time flexible cystoscopy (a thin tube inserted into the bladder). Researchers will ask 150 adults to rate their expected and actual pain using a simple 0-10 scale. The goal is to better understand who mig…

This study looks at kidney cancer tumors that have multiple small nodules inside them. Researchers will take samples from 10 patients and use advanced gene mapping to see if the nodules are different. They will also grow tiny 3D tumor models in the lab to test how they respond to…

This study looks at 860 Chinese patients with advanced kidney cancer to see which order of treatments works better: starting with one drug combo and switching to another, or the reverse. The goal is to find the best sequence to help patients live longer and feel better. Participa…

This observational study will follow 150 adults with early-stage bladder cancer to see if factors like muscle loss, fat distribution, and nutrition affect the chance of cancer coming back or getting worse. Participants will have standard treatments and extra assessments including…

This study reviews medical records of 87 adults with muscle-invasive bladder cancer who received platinum-based chemotherapy before surgery. Researchers want to see what factors influence how well the chemo works and whether it helps patients live longer without cancer. The goal …

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…

This observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …

This early study will look at how two drugs, cabozantinib and nivolumab, change the bone immune environment in 16 people with kidney cancer that has spread to bone. The main goal is to check safety and see how the bone environment responds. It is a proof-of-concept study, meaning…

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…